{"id":"NCT01186744","sponsor":"Pfizer","briefTitle":"A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis","officialTitle":"A Phase 3, Multi-Site, Randomized, Mixed-Blind, Parallel-Group Treatment Withdrawal And Re-Treatment Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2013-01","completion":"2013-01","firstPosted":"2010-08-23","resultsPosted":"2014-06-04","lastUpdate":"2018-12-26"},"enrollment":666,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"CP-690,550","otherNames":[]}],"arms":[{"label":"Active Treatment (10 mg) BID / Placebo BID","type":"EXPERIMENTAL"},{"label":"Active Treatment (10 mg) BID","type":"EXPERIMENTAL"},{"label":"Active Treatment (5 mg) BID / Placebo BID","type":"EXPERIMENTAL"},{"label":"Active Treatment (5 mg) BID","type":"EXPERIMENTAL"}],"summary":"The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at various timepoints during the 16 week double blind active or placebo treatment period; 2) evaluate the regain of efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) following 4 -16 weeks of CP 690,550 treatment withdrawal and subsequent re treatment; and 3) evaluate the safety and tolerability of CP 690,550 (5 mg BID and 10 mg BID) in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.","primaryOutcome":{"measure":"Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)","timeFrame":"Weeks 4, 8 12, and 16 (Period B)","effectByArm":[{"arm":"CP-690,550 5 mg (Period B)","deltaMin":90.3,"sd":null},{"arm":"Placebo for CP-690,550 5 mg (Period B)","deltaMin":63.4,"sd":null},{"arm":"CP-690,550 10 mg (Period B)","deltaMin":91.1,"sd":null},{"arm":"Placebo for 10 mg CP-690,550","deltaMin":61.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0008"},{"comp":"OG002 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":87,"countries":["United States","Argentina","Australia","Brazil","Bulgaria","Canada","Denmark","Finland","Greece","Netherlands","Slovakia","United Kingdom"]},"refs":{"pmids":["32816215","25418186"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921111&StudyName=A%20Phase%203%2C%20Multi-Site%2C%20Randomized%2C%20Mixed-Blind%2C%20Parallel-Group%20Treatment%20Withdrawal%20And%20Re-Treatment%20Study%20Of%20The%20Efficacy%20And%20Safety%20Of%202%20Oral%20Doses%20Of%20CP-690%2C550%20In%20Subjects%20With%20Moderate%20To%20Severe%20Chronic%20Plaque%20Psoriasis"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":218},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Blood creatine phosphokinase increased","Headache","Urinary tract infection"]}}